• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Lower Revenue And A Net Loss Will Impact Septerna (SEPN) Investors

    Simply Wall St·11/10/2026 07:12:49
    Listen to the news
    • Septerna reported third quarter 2026 sales of US$18.88 million, down from US$21.5 million a year earlier. The company also shifted from US$8.17 million in net income to a net loss of US$26.59 million and moved from earnings to a loss of US$0.57 per share.
    • Across the first nine months of 2026, Septerna generated US$72.15 million in sales compared with US$21.83 million a year prior. However, it recorded a wider net loss of US$48.26 million and a higher loss per share, indicating costs or investment that exceeded revenue.
    • This context helps frame how Septerna's investment narrative aligns with the latest earnings report and the return to losses.

    Scan beyond Septerna and line up peers facing similar earnings pressure with the hand-picked 30 resilient stocks with low risk scores that may offer a different balance between resilience and downside.

    Septerna Investment Narrative Recap

    To own Septerna, you need to be comfortable with a biotech story where pipeline progress matters more than near term profits. The analyst consensus narrative on Simply Wall St anchors that view on SEP-479 in hypoparathyroidism and SEP-631 in mast cell diseases. The latest quarter shows higher losses alongside solid year to date sales, which keeps attention firmly on cash use and trial execution.

    The short term swing factor still sits with early SEP-479 safety and dosing data and whether SEP-631 advances cleanly into planned urticaria studies. The wider net loss in the third quarter does not change those scientific milestones, but it does sharpen focus on how long Septerna can fund multiple programs before needing extra capital.

    The fresh earnings release is the clearest recent marker for where Septerna stands against that pipeline narrative. Nine month sales of US$72.15 million versus US$21.83 million a year earlier show a larger revenue base, yet the reported net loss of US$48.26 million and higher loss per share underline that development and operating spend are running ahead of income.

    For catalysts, those figures frame how much financial headroom exists while SEP-479, SEP-631, the TSH receptor program and the Novo Nordisk partnership move through their next steps. The deeper loss profile heightens the risk that setbacks in any of these areas, especially a weak SEP-479 Phase 1 outcome, could leave Septerna with rising costs and limited offsetting revenue opportunities.

    What the Analyst Models Assume for Septerna

    Septerna's narrative projects US$48.5 million revenue and US$8.3 million earnings by 2029. This would require a 21.1% yearly revenue decline and an earnings swing of about US$32.5 million from current earnings of a US$24.2 million loss.

    Uncover why Septerna's fair value indicates a 7% potential upside to its current price that could narrow quickly.

    NasdaqGM:SEPN 1-Year Stock Price Chart
    NasdaqGM:SEPN 1-Year Stock Price Chart

    Exploring Other Perspectives

    Two fair value estimates from the Simply Wall St Community cluster tightly between US$54.22 and US$56.78, so retail views on Septerna are currently narrow rather than spread across extremes. Those opinions were formed before the latest widening losses and upcoming conference appearance. You should explore fresh viewpoints as the trial and partnership news flow evolves.

    Explore another Septerna fair value estimate, including one that suggests as much as 12% upside from the current price.

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    • A great starting point for your Septerna research is our analysis highlighting 2 important warning signs that could impact your investment decision.
    • See our latest analysis for Septerna. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Septerna's overall financial health at a glance.

    Looking for more ideas beyond Septerna?

    Once you have a view on Septerna, it can help to set it alongside other opportunities that line up with your own risk, income, and quality preferences. The Simply Wall St Screener lets you do that quickly using curated sets of stocks.